Uterus/ Endometrium Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
Select
12-1650 GOG 275: A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Select
12-1419 GOG 277: A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma
Select
IRB14-0712 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
09-123-B Long Term Database Collection for Endometrial Cancer
Select
10-627-A GOG 8013: Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression As Well As Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated with Anthracycline-Based Therapy
12-1767 Endometrial Cancer Survivorship: A Qualitative Approach to Understanding Healthy Lifestyle Change in African American Endometrial Cancer Survivors and Their Support Network
IRB13-1323 NCI 9322: A phase 2 study of XL184 (Cabozantinib) in recurrent or Metastatic Endometrial Cancer
IRB14-1418 GOG Partners 3007: A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/ Medroxyprogesterone Acetate) in Women with Advanced, Persistent, or Recurrent Endometrial Carcinoma
12-1950 Endometrial Cancer Survivorship: Reducing Obesity and Reducing Disparity
12-1157 Topoisomerase 2A (TOPO2A) Amplification/Overexpression and Other Predictive/Prognostic Markers in Women with Endometrial Cancer
Select
IRB15-0063 NRG-CC002: Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team